Skip to main content
Premium Trial:

Request an Annual Quote

Aclara, Punished by Lawsuit Settlement Costs, Posts Bruising Q2 Losses

NEW YORK, Aug. 1 - Aclara Biosciences reported a reduction in total second-quarter revenue atop increased R&D spending and a significantly widened net loss.

For the three months ended June 30, Aclara reported total revenues of $673,000 compared with $849,000 for the same period one year ago. R&D spending in the quarter increased to $6.4 million from $5.5 million year over year. In addition, the company was forced to shell out $1.8 million as part of a settlement of a lawsuit with with Caliper Technologies last January.

As a result, net loss in the quarter ballooned to $9.9 million, or $.27 per share, from $3.2 million, or $.09 per share, in the second quarter 2001, Aclara said.

 

Aclara, which yesterday said announced plans to lay off 50 of its staff as it redirects its business strategy away from microfluidics, had roughly $45.8 million in cash and cash equivalents as of June 30.

 

Click here for more information.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.